Table 1.
Clinical Characteristics of Aspirin‐ Versus Non‐Aspirin‐Treated Patients
| Variables | Aspirin Group n=390 Patients | Nonaspirin Group n=615 Patients | P Value |
|---|---|---|---|
| Age, y | 73.6±17.4 | 75.3±12.8 | 0.08 |
| Male sex | 215 (55.1%) | 375 (61.0%) | 0.067 |
| PSI II to III classes | 130 (33.3%) | 58 (9.4%) | <0.001 |
| PSI IV class | 206 (52.8%) | 299 (48.6%) | 0.194 |
| PSI V class | 54 (13.8%) | 258 (42.0%) | <0.001 |
| CURB‐65 I class | 195 (50%) | 219 (35.6%) | <0.001 |
| CURB‐65 II class | 153 (39.2%) | 211 (34.3%) | 0.1 |
| CURB‐65 III class | 42 (10.7%) | 185 (30.1%) | <0.001 |
| Chronic heart disease | 175 (44.9%) | 134 (21.7%) | <0.01 |
| Chronic hepatitis | 31 (7.9%) | 61 (9.9%) | 0.8 |
| Diabetes | 41 (10.5%) | 151 (24.5%) | <0.001 |
| Renal failure | 62 (16%) | 131 (21.3%) | 0.1 |
| COPD | 128 (32.8%) | 198 (32.2%) | 0.8 |
| CAP | 271 (69.4%) | 356 (57.8%) | 0.02 |
| HCAP | 119 (30.5%) | 259 (42.2%) | 0.03 |
| Neoplasm | 50 (12.9%) | 179 (29.1%) | <0.001 |
| Pleural effusion | 86 (22.1%) | 338 (54.9%) | <0.001 |
| Immunosuppressive therapy | 52 (13.3%) | 84 (13.6%) | 0.5 |
| Fever >38°C | 224 (57.4%) | 330 (53.6%) | 0.5 |
| PaO2/FiO2 ratio <300 | 26 (6.6%) | 156 (25.3%) | <0.001 |
| NIV | 2 (0.5%) | 29 (4.7%) | <0.001 |
| SOFA score >2 | 142 (36.4%) | 503 (81.8%) | <0.001 |
| Severe sepsis or septic shock | 18 (4.6%) | 71 (11.5%) | <0.001 |
| Nonfatal cardiovascular events | 19 (4.9%) | 51 (8.3%) | 0.03 |
CAP indicates community‐acquired pneumonia; COPD, chronic obstructive pulmonary disease; HCAP, healthcare‐associated pneumonia; NIV, noninvasive ventilation; PSI, pneumonia severity index; SOFA, Sequential Organ Failure Assessment.